KindlyMD (NASDAQ:NAKA) Price Target Raised to $17.00

KindlyMD (NASDAQ:NAKA) had its price target raised by TD Cowen from $1.00 to $17.00 in a research note released on Monday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts also recently issued reports about the company. Maxim Group dropped their target price on KindlyMD from $60.00 to $30.00 and set a “buy” rating for the company in a research report on Monday, April 6th. Weiss Ratings raised KindlyMD from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, Wall Street Zen upgraded shares of KindlyMD to a “sell” rating in a research report on Saturday, May 23rd. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $22.33.

KindlyMD Price Performance

NAKA stock opened at $4.28 on Monday. The stock has a market cap of $74.47 million, a price-to-earnings ratio of -0.10 and a beta of 16.05. The company has a 50 day simple moving average of $4.56 and a 200 day simple moving average of $8.57. KindlyMD has a 1 year low of $3.33 and a 1 year high of $659.20.

KindlyMD (NASDAQ:NAKA) last posted its earnings results on Wednesday, May 13th. The company reported ($0.38) earnings per share for the quarter. The company had revenue of $2.68 million for the quarter. KindlyMD had a negative return on equity of 81.32% and a negative net margin of 7,397.12%. On average, equities research analysts anticipate that KindlyMD will post -16.8 EPS for the current fiscal year.

Insider Transactions at KindlyMD

In other news, CEO David F. Bailey purchased 104,833 shares of the business’s stock in a transaction on Wednesday, May 27th. The shares were acquired at an average price of $4.84 per share, with a total value of $507,391.72. Following the completion of the transaction, the chief executive officer owned 3,120,361 shares of the company’s stock, valued at $15,102,547.24. The trade was a 3.48% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have acquired a total of 191,448 shares of company stock valued at $992,908 in the last quarter. 24.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC bought a new stake in KindlyMD in the fourth quarter worth approximately $61,000. Virtu Financial LLC acquired a new stake in shares of KindlyMD during the 4th quarter worth approximately $151,000. J. Derek Lewis & Associates Inc. bought a new stake in shares of KindlyMD in the 4th quarter valued at $167,000. Truist Financial Corp bought a new stake in shares of KindlyMD in the 4th quarter valued at $176,000. Finally, Waddell & Associates LLC acquired a new position in shares of KindlyMD during the 4th quarter valued at $201,000.

About KindlyMD

Kindly MD, Inc (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis.